The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Advances in the science and treatment of alcohol use disorder
Open accessAbstract
Pharmacological and behavioral treatments exist for alcohol use disorder, but more are needed, and several are under development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
(1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.7 · Cited by 1,905
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
2010 National and State Costs of Excessive Alcohol Consumption
Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer, R. D. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.05.031 · Cited by 1,180
Economic costs of excessive alcohol consumption in the U.S., 2006
Bouchery, E. E., Harwood, H. J., Sacks, J. J., Simon, C. J., & Brewer, R. D. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.06.045 · Cited by 1,041
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Relapse Prevention for Alcohol and Drug Problems: That Was Zen, This Is Tao
Witkiewitz, K., & Marlatt, G. A. (2004) · American Psychologist · doi:10.1037/0003-066x.59.4.224 · Cited by 880
Self-citationMesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders
Miller, W. R., & Wilbourne, P. L. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00019.x · Cited by 805
Alcoholism: Allostasis and Beyond
Koob, G. F. (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000057122.36127.c2 · Cited by 737
Magill, M., & Ray, L. A. (2009) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2009.70.516 · Cited by 694
A Smartphone Application to Support Recovery From Alcoholism: A Randomized Clinical Trial
Gustafson, D. H., McTavish, F. M., Chih, M.-Y., Atwood, A. K., Johnson, R. A., Boyle, M. G., Levy, M. S., Driscoll, H., Chisholm, S. M., Dillenburg, L., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4642 · Cited by 692
Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D'Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 685
Self-citationDiagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Harm reduction approaches to alcohol use
Marlatt, G. A., & Witkiewitz, K. (2002) · Addictive Behaviors · doi:10.1016/s0306-4603(02)00294-0 · Cited by 491
Self-citationMaisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders
Kwako, L. E., Momenan, R., Litten, R. Z., Koob, G. F., & Goldman, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.024 · Cited by 395
Self-citationJonas, D. E., Garbutt, J. C., Amick, H. R., Brown, J. M., Brownley, K. A., Council, C. L., Viera, A. J., Wilkins, T. M., Schwartz, C. J., Richmond, E. M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00544 · Cited by 387
Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340
Kelly, J. F., Bergman, B. G., Hoeppner, B. B., Vilsaint, C., & White, W. L. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.09.028 · Cited by 339
Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330
Self-citationLitten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287
Self-citationA Systematic Review of the mHealth Interventions to Prevent Alcohol and Substance Abuse
Kazemi, D. M., Borsari, B., Levine, M. J., Li, S., Lamberson, K. A., & Matta, L. A. (2017) · Journal of Health Communication · doi:10.1080/10810730.2017.1303556 · Cited by 255
Fernández, A. J. C., Marcos, M., Mirón‐Canelo, J., Pastor, I., González‐Sarmiento, R., & Laso, F. J. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00442.x · Cited by 234
Using transtheoretical model profiles to differentiate levels of alcohol abstinence success.
Carbonari, J. P., & DiClemente, C. C. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.68.5.810 · Cited by 219
Identification and Management of Alcohol Withdrawal Syndrome
Mirijello, A., D’Angelo, C., Ferrulli, A., Vassallo, G., Antonelli, M., Caputo, F., Leggio, L., Gasbarrini, A., & Addolorato, G. (2015) · Drugs · doi:10.1007/s40265-015-0358-1 · Cited by 200
Self-citationWitkin, J. M., Statnick, M. A., Rorick-Kehn, L. M., Pintar, J. E., Ansonoff, M., Chen, Y., Tucker, R. C., & Ciccocioppo, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.011 · Cited by 194
Johnson, B. A., Ait-Daoud, N., Seneviratne, C., Roache, J. D., Javors, M. A., Wang, X.-Q., Liu, L., Penberthy, J. K., DiClemente, C. C., & Li, M. D. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050755 · Cited by 189
Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler, H. R., Covault, J., Feinn, R., Armeli, S., Tennen, H., Arias, A. J., Gelernter, J., Pond, T., Oncken, C., & Kampman, K. M. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13081014 · Cited by 184
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Distinctions without a difference: Direct comparisons of psychotherapies for alcohol use disorders.
Imel, Z. E., Wampold, B. E., Miller, S. D., & Fleming, R. R. (2008) · Psychology of Addictive Behaviors · doi:10.1037/a0013171 · Cited by 172
Kranzler, H. R., Wesson, D. R., Billot, L., & DrugAbuse Sciences Naltrexone Depot Study Group (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000130804.08397.29 · Cited by 169
Witkiewitz, K. A., Hallgren, K. A., Kranzler, H. R., Mann, K. F., Hasin, D. S., Falk, D. E., Litten, R. Z., O’Malley, S. S., & Anton, R. F. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13272 · Cited by 166
Self-citationAlcohol Use Disorders in Primary Health Care: What Do We Know and Where Do We Go?
Rehm, J., Anderson, P., Manthey, J., Shield, K. D., Struzzo, P., Wojnar, M., & Gual, A. (2016) · Alcohol and Alcoholism · doi:10.1093/alcalc/agv127 · Cited by 163
Baclofen for the treatment of alcohol use disorder: the Cagliari Statement
Agabio, R., Sinclair, J., Addolorato, G., Aubin, H., Beraha, E. M., Caputo, F., Chick, J., Selle, P. D. L., Franchitto, N., Garbutt, J. C., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30303-1 · Cited by 146
Self-citationMann, K. F., Roos, C. R., Hoffmann, S., Nakovics, H., Leménager, T., Heinz, A., & Witkiewitz, K. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.282 · Cited by 137
Self-citationEfficacy of invasive and non-invasive brain modulation interventions for addiction
Luigjes, J., Segrave, R., de Joode, N., Figee, M., & Denys, D. (2019) · Neuropsychology Review · doi:10.1007/s11065-018-9393-5 · Cited by 125
Morley, K. C., Baillie, A., Fraser, I. S., Furneaux-Bate, A., Dore, G., Roberts, M. S., Abdalla, A., Phung, N., & Haber, P. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.13 · Cited by 125
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial
Oslin, D. W., Leong, S. H., Lynch, K. G., Berrettini, W. H., O’Brien, C. P., Gordon, A. J., & Rukstalis, M. R. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3053 · Cited by 123
Falk, D. E., O’Malley, S. S., Witkiewitz, K., Anton, R. F., Litten, R. Z., Slater, M., Kranzler, H. R., Mann, K. F., Hasin, D. S., Johnson, B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3079 · Cited by 120
Self-citationEffectiveness and Safety of Baclofen in the Treatment of Alcohol Dependent Patients
Leggio, L., Garbutt, J. C., & Addolorato, G. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966614 · Cited by 119
Self-citationMann, K., Lemenager, T., Hoffmann, S., Reinhard, I., Hermann, D., Batra, A., Berner, M., Wodarz, N., Heinz, A., Smolka, M., et al. (2013) · Addiction Biology · doi:10.1111/adb.12012 · Cited by 118
Noradrenergic targets for the treatment of alcohol use disorder
Haass-Koffler, C. L., Swift, R. M., & Leggio, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4843-6 · Cited by 117
Self-citationMason, B. J., Light, J. M., Williams, L. D., & Drobes, D. J. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00133.x · Cited by 115
Schmidt, C. S., Schulte, B., Seo, H., Kuhn, S., O'Donnell, A., Kriston, L., Verthein, U., & Reimer, J. (2016) · Addiction · doi:10.1111/add.13263 · Cited by 107
Varenicline for Treatment of Alcohol Dependence: A Randomized, Placebo‐Controlled Trial
de Bejczy, A., Löf, E., Walther, L., Guterstam, J., Hammarberg, A., Asanovska, G., Franck, J., Isaksson, A., & Söderpalm, B. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12854 · Cited by 107
Stress-Related Neuropeptides and Addictive Behaviors: Beyond the Usual Suspects
Schank, J. R., Ryabinin, A. E., Giardino, W. J., Ciccocioppo, R., & Heilig, M. A. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.026 · Cited by 107
Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder
Farokhnia, M., Faulkner, M. L., Piacentino, D., Lee, M. R., & Leggio, L. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.02.008 · Cited by 107
Self-citationAssessment and treatment of mood disorders in the context of substance abuse
Tolliver, B. K., & Anton, R. F. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/btolliver · Cited by 105
Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date
Lee, M. R., Rohn, M. C. H., Tanda, G., & Leggio, L. (2016) · CNS Drugs · doi:10.1007/s40263-016-0313-z · Cited by 103
Self-citationPalpacuer, C., Laviolle, B., Boussageon, R., Reymann, J. M., Bellissant, E., & Naudet, F. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001924 · Cited by 102
Mann, K. F., Torup, L., Sørensen, P. S., Gual, A., Swift, R. M., Walker, B. M., & van den Brink, W. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.008 · Cited by 101
High-dose naltrexone therapy and dietary counseling for obesity
Mitchell, J. E., Morley, J. E., Levine, A. S., Hatsukami, D., Gannon, M. C., & Pfohl, D. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90127-2 · Cited by 100
Hennessy, E. A., Tanner‐Smith, E. E., Mavridis, D., & Grant, S. (2019) · Prevention Science · doi:10.1007/s11121-018-0960-z · Cited by 97
Kiluk, B. D., Devore, K. A., Buck, M. B., Nich, C., Frankforter, T. L., LaPaglia, D. M., Yates, B. T., Gordon, M. A., & Carroll, K. M. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13162 · Cited by 96
O’Malley, S. S., Zweben, A., Fucito, L. M., Wu, R., Piepmeier, M. E., Ockert, D. M., Bold, K. W., Petrakis, I. L., Muvvala, S. B., Jatlow, P. I., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3544 · Cited by 94
Falk, D. E., Ryan, M. L., Fertig, J. B., Devine, E. G., Cruz, R., Brown, E. S., Burns, H., Salloum, I. M., Newport, D. J., Mendelson, J., et al. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13917 · Cited by 89
Self-citationSoyka, M., Kranzler, H. R., HESSELBROCK, V. M., Kasper, S. F., Mutschler, J., Möller, H., & The WFSBP Task Force on Treatment Guidelines for Substance Use Disorders (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1246752 · Cited by 87
Targeted Naltrexone for Problem Drinkers
Kranzler, H. R., Tennen, H. A., Armeli, S., Chan, G., Covault, J., Arias, A. J., & Oncken, C. A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ac5213 · Cited by 85
Garbutt, J. C., Greenblatt, A. M., West, S. L., Morgan, L. C., Kampov‐Polevoy, A. B., Jordan, H. S., & Bobashev, G. (2014) · Addiction · doi:10.1111/add.12557 · Cited by 83
A contextual model of self-regulation change mechanisms among individuals with addictive disorders
Roos, C. R., & Witkiewitz, K. A. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.08.008 · Cited by 78
Self-citationAnton, R. F., Myrick, H., Baros, A. M., Latham, P. K., Randall, P. K., Wright, T. M., Stewart, S., Waid, R., & Malcolm, R. J. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181aba6a4 · Cited by 77
The microbiota, the gut and the brain in eating and alcohol use disorders: A ‘Ménage à Trois’?
Temko, J. E., Bouhlal, S., Farokhnia, M., Lee, M. R., Cryan, J. F., & Leggio, L. (2017) · Alcohol and Alcoholism · doi:10.1093/alcalc/agx024 · Cited by 76
Magill, M., Kiluk, B. D., McCrady, B., Tonigan, J., & Longabaugh, R. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12848 · Cited by 76
Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
Kenna, G. A., Lomastro, T., Schiesl, A., Leggio, L., & Swift, R. M. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902020135 · Cited by 75
Self-citationBaclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73
GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
Jerlhag, E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.013 · Cited by 72
Treatment Seeking for Alcohol Use Disorders: Treatment Gap or Adequate Self-Selection?
Tuithof, M., ten Have, M., van den Brink, W., Vollebergh, W., & de Graaf, R. (2016) · European Addiction Research · doi:10.1159/000446822 · Cited by 70
Litten, R. Z., Castle, I. P., Falk, D. E., Ryan, M., Fertig, J. B., Chen, C. M., & Yi, H. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12197 · Cited by 63
Self-citationAligning the ICD-11 classification of disorders due to substance use with global service needs
Poznyak, V., Reed, G. M., & Medina-Mora, M. E. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796017000622 · Cited by 62
Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 62
Techniques to Enhance Compliance with Disulfiram
Allen, J. P., & Litten, R. Z. (1992) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1992.tb00695.x · Cited by 61
Self-citationFalk, D. E., Castle, I. P., Ryan, M., Fertig, J. B., & Litten, R. Z. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000133 · Cited by 61
Self-citationRoos, C. R., Mann, K. F., & Witkiewitz, K. A. (2016) · Addiction Biology · doi:10.1111/adb.12427 · Cited by 60
Self-citationDysregulation of brain stress systems mediates compulsive alcohol drinking
Tunstall, B. J., Carmack, S. A., Koob, G. F., & Vendruscolo, L. F. (2017) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.10.006 · Cited by 55
Effect of Extended‐Release Naltrexone (XR‐NTX) on Quality of Life in Alcohol‐Dependent Patients
Pettinati, H. M., Gastfriend, D. R., Dong, Q., Kranzler, H. R., & O’Malley, S. S. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00843.x · Cited by 54
Nonmedical prescription sedative/tranquilizer use in alcohol and opioid use disorders
Votaw, V. R., Witkiewitz, K. A., Valeri, L., Bogunovic, O. J., & McHugh, R. K. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.010 · Cited by 52
Self-citationPlacebo-Controlled Trial of Zonisamide for the Treatment of Alcohol Dependence
Arias, A. J., Feinn, R., Oncken, C. A., Covault, J., & Kranzler, H. R. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181db38bb · Cited by 50
Twelve Defining Moments in the History of Alcoholics Anonymous
White, W. L., & Kurtz, E. (2008) · Recent developments in alcoholism · doi:10.1007/978-0-387-77725-2_3 · Cited by 48
Overcoming the “Valley of Death” in Medications Development for Alcohol Use Disorder
Ray, L. A., Bujarski, S., Roche, D. J. O., & Magill, M. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13829 · Cited by 46
Tanner‐Smith, E. E., & Risser, M. D. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2015.1136638 · Cited by 42
Mindfulness-based interventions for addictive behaviors: implementation issues on the road ahead
Wilson, A. D., Roos, C. R., Robinson, C. S., Stein, E. R., Manuel, J. A., Enkema, M. C., Bowen, S., & Witkiewitz, K. (2017) · Psychology of Addictive Behaviors · doi:10.1037/adb0000319 · Cited by 41
Kenna, G. A., Zywiak, W. H., Swift, R. M., McGeary, J. E., Clifford, J. S., Shoaff, J. R., Vuittonet, C. L., Fricchione, S. R., Brickley, M., Beaucage, K., et al. (2014) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12410 · Cited by 40
Self-citationKenna, G. A., Swift, R. M., Hillemacher, T., & Leggio, L. (2012) · Neuropsychology Review · doi:10.1007/s11065-012-9209-y · Cited by 38
Self-citationPsychosocial approaches to alcohol use disorders since 1940: a review
McCrady, B. S., Owens, M. D., Borders, A. Z., & Brovko, J. M. (2014) · Journal of Studies on Alcohol and Drugs, Supplement · doi:10.15288/jsads.2014.s17.68 · Cited by 37
Farokhnia, M., Deschaine, S. L., Sadighi, A., Farinelli, L. A., Lee, M. R., Akhlaghi, F., & Leggio, L. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0287-y · Cited by 37
Self-citationNaltrexone and Nalmefene: Any Meaningful Difference?
Swift, R. M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.002 · Cited by 34
Soyka, M., Friede, M., & Schnitker, J. (2016) · Pharmacopsychiatry · doi:10.1055/s-0035-1565184 · Cited by 34
Behavioral therapy across the spectrum.
Witkiewitz, K. A., & Marlatt, A. G. (2011) · Europe PMC (PubMed Central) · Cited by 32
Self-citationAdvances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 31
Self-citationAlcohol Use Trajectories Among Non–Treatment-Seeking Heavy Drinkers
Witkiewitz, K. A., Dearing, R. L., & Maisto, S. A. (2014) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2014.75.415 · Cited by 30
Self-citationMagill, M., Bernstein, M. H., Hoadley, A., Borsari, B. E., Apodaca, T. R., Gaume, J., & Tonigan, J. S. (2018) · Psychotherapy Research · doi:10.1080/10503307.2018.1490973 · Cited by 30
Wu, J., & Witkiewitz, K. (2008) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2008.69.21 · Cited by 29
Self-citationAnton, R. F., Latham, P. K., Voronin, K. E., Randall, P. K., Book, S. W., Hoffman, M., & Schacht, J. P. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13601 · Cited by 29
Sloan, M. E., Klepp, T., Gowin, J. L., Swan, J. E., Sun, H., Stangl, B. L., & Ramchandani, V. A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-017-0002-8 · Cited by 29
Devine, E. G., Ryan, M. L., Falk, D. E., Fertig, J. B., & Litten, R. Z. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.08.006 · Cited by 28
Self-citationJonas, D. E., Amick, H. R., Feltner, C., Wines, R., Shanahan, E., Rowe, C. J., & Garbutt, J. C. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.121 · Cited by 26
Worley, M. J., Witkiewitz, K. A., Brown, S. A., Kivlahan, D. R., & Longabaugh, R. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12605 · Cited by 20
Self-citationBaclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557 · Cited by 19
Investigational drugs for alcohol use disorders: a review of preclinical data
Ch’ng, S. S., & Lawrence, A. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1472763 · Cited by 15
Cited by
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4789 · Cited by 287
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Self-citationEffects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
Bohnsack, J. P., Zhang, H., Wandling, G. M., He, D., Kyzar, E. J., Lasek, A. W., & Pandey, S. C. (2022) · Science Advances · doi:10.1126/sciadv.abn2748 · Cited by 68
Magill, M., Kiluk, B. D., & Ray, L. A. (2023) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s362864 · Cited by 50
“…these secondary measures of clinical benefit, and given recent dialog around what constitutes an optimal outcome metric in addiction research 24,25 as well as interest in operationalizing the construct of recovery as beyond and not requiring abstinence, 26 this is a limitation of the current…”
Metadata
- Authors
- Witkiewitz, K., Litten, R. Z., & Leggio, L.
- Venue
- Science Advances
- Published
- 2019-09-06
- Volume
- 5
- Issue
- 9
- Pages
- eaax4043-eaax4043
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W2977087053
- Cited by
- 592
- References
- 106
- FWCI
- 34.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.